Análise de eficácia de acordo com valores de TMB no CheckMate 9LA

O tumor mutation burden (TMB) está potencialmente associado à eficácia clínica dos inibidores de correceptores imunes. Durante o ELCC 2022, foram apresentados os dados de eficácia da combinação de nivolumabe + ipilimumabe + quimioterapia segundo os valores de TMB tanto do tecido tumoral quanto do sangue dos pacientes.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial - The Lancet Oncology

Ana Moreno (@superanitamix) / X

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

PDF) Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations: Tumor mutational burden in NSCLC

CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy

Rapid Readouts: CheckMate 9LA

Arquivo de GBCP - GBCP

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Caminhos da Matemática: História, Educação e Aplicações

Arquivo de GBCP - GBCP

CheckMate 9LA: análise da combinação de imunoterapia e quimioterapia em pacientes com e sem metástases cerebrais - Oncologia Brasil